Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention
- 15 March 2004
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 93 (6), 679-684
- https://doi.org/10.1016/j.amjcard.2003.11.048
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Scientific and therapeutic advances in antiplatelet therapyNature Reviews Drug Discovery, 2003
- Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary InterventionJAMA, 2002
- Death Following Creatine Kinase-MB Elevation After Coronary InterventionCirculation, 2002
- Clopidogrel, but not abciximab, reduces platelet leukocyte conjugates and P‐selectin expression in a human ex vivo in vitro modelClinical Pharmacology & Therapeutics, 2002
- CD40L stabilizes arterial thrombi by a β3 integrin–dependent mechanismNature Medicine, 2002
- Platelet CD40 ligand (CD40L) – subcellular localization, regulation of expression, and inhibition by clopidogrelPlatelets, 2001
- Interleukin 6 expression in coronary circulation after coronary angioplasty as a risk factor for restenosisHeart, 2000
- Requirement for CD154 in the progression of atherosclerosisNature Medicine, 1999
- Enhanced Levels of Soluble and Membrane-Bound CD40 Ligand in Patients With Unstable AnginaCirculation, 1999
- Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA.Circulation, 1993